HIGHLIGHTS
- who: Csaba Csikos and collaborators from the Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of, have published the research: In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model, in the Journal: Diagnostics 2023, 236 of 17/Dec/2022
- what: The aim of the preclinical study was to assess the biodistribution and tumor-targeting potential of 52 Mn-labeled DOTAGA-bevacizumab.
SUMMARY
Mainly through VEGFR-2, signaling pathways can become . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.